Biocon Limited has informed the Exchange regarding a press release dated April 10, 2025, titled "Biocon Biologics Announces U.S. FDA Approval for Jobevne , Biosimilar Bevacizumab, Expanding Its Oncology Portfolio".
Press Release Apr 10 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Biocon
- Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
- Press Release Mar 07 2025
- Press Release Mar 06 2025
- Press Release Mar 04 2025
- Press Release Feb 28 2025
Later from Biocon
- Biocon Limited Press Release Apr 15 2025
- Biocon Limited Press Release May 05 2025
- Press Release May 08 2025
- Press Release Jun 09 2025
- Press Release Jun 20 2025
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon